Ariagenbio

Shutdown

Website unreachable since Oct 30, 2026

The startup is developing a novel class of small immunotherapies that target specific cancer cell pathways to enhance the immune response against tumors. This approach aims to improve treatment efficacy while minimizing side effects associated with traditional cancer therapies.

Traction –/10

Menlo Park, United States · HQ

Biotechnology

Updated 5 months ago

Funding

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Features

The startup is developing a novel class of small immunotherapies that target specific cancer cell pathways to enhance the immune response against tumors. This approach aims to improve treatment efficacy while minimizing side effects associated with traditional cancer therapies.